Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon

Backgraund: Children with type 1 diabetes mellitus (T1DM) need more insulin late in the evening (reverse dawn phenomenon (RDP)), and adolescents need more insulin yearly in the morning (dawn phenomenon (DP)); these cause blood glucose variability. Modern long acting insulin analogues allow to achieve satisfactory glycemic control.

Aims: To study the characteristics of insulin therapy in children and adolescents with T1DM using insulin analogues detemir and degludec to overcome blood glucose variability caused by DP and RDP in different age periods.

Materials and methods: We analyzed medical documents of 200 patients using detemir, admitted to pediatric endocrinology department in 2013–2019, at mean age 9.0 years (5.4; 13.0), with T1DM for 1.3 years (0.5; 3.0); and medical documents of 50 patients switched to degludec in 2018–2019 at mean age 12.0 years (10.5; 14.5) with T1DM for 3.0 years (1.5; 6.0). Before degludec they were on intensive insulin therapy with glargine (22), detemir (26), or insulin pump (2); 16 patients (32%) presented with clinical characteristics of DP, and 5 (10%) — RDP.

Results: 67 children of 108 (62%) aged 1–9 years had redistribution of detemir doses to daytime; 58 adolescents of 92 (63%) aged 10–17 лет — to nighttime. Patients switched to degludec demonstrated decrease in HbA1с from 8.7% (7.8; 9.9) to 8.0% (7.4; 9.0) (р<0.001); fasting blood glucose from 9.8 mmol/l (7.4; 11.7) to 7.7 mmol/l (6.4; 8.6) (р<0.001); within-day variability from 35.2% (31.6; 40.9) to 23.5% (19.7; 28.6) (р<0.001); daily insulin dose from 0.98 U/kg/day (0.82; 1.14) to 0.87 U/kg/day (0.75; 1.07) (р=0.002). Sub-groups of patients with DP and RDP demonstrated decrease in fasting blood glucose (from 11.5 mmol/l (9.8; 13.8) to 7.5 mmol/l (6.6; 9.1) (р<0.001)), and late evening blood glucose (from 11.0 mmol/l (10.2; 11.2) to 8.0 mmol/l (6.7; 9.5) (р= 0.03)) correspondently. Achieved levels of glycemic control did not differ between sub-groups of patients initially using glargine or detemir.

Conclusions: Compensation of T1DM may be complicated due to DP and RDP. Switching to degludec allowed to achieve better glycemic control and lowering of blood glucose variability caused by DP and DRP.

1. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Клинические рекомендации (Вып. 9) // Сахарный диабет. — 2019. — Т. 22. — №S1. — С.1-144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.)]. doi: https://doi.org/10.14341/DM221S1

2. Анциферов М.Б., Галстян Г.Р., Зилов А.В., и др. Резолюция по итогам первой рабочей встречи Научно-консультативного совета по вопросу «Актуальные проблемы вариабельности гликемии как нового критерия гликемического контроля и безопасности терапии сахарного диабета» // Сахарный диабет. — 2019. — Т. 22. — №3. — С. 281-288. [Antsiferov MB, Galstyan GR, Zilov AV, et al. Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy». Diabetes Mellitus. 2019;22(3):281-288 (In Russ.)]. doi: https://doi.org/10.14341/DM10227

3. Bailey T, Bhargava A, Devries JH, et al. Within-day Variability Based on 9-point Profiles Associates with Overall and Nocturnal Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Can J Diabetes. 2017;41(5):S7. doi: https://doi.org/10.1016/j.jcjd.2017.08.022

4. Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Research and Clinical Practice. 2005;69(1);14-21. doi: https://doi.org/10.1016/j.diabres.2004.11.005

5. Nicolajsen T, Samuelsson A, Hanas R. Insulin Doses before and One Year after Pump Start: Children Have a Reversed Dawn Phenomenon. J Diabetes Sci Technol. 2012;6(3):589-594. doi: https://doi.org/10.1177/193229681200600314

6. Danne T, Bangstad H-J, Deeb L, et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(S20):115-134. doi: https://doi.org/10.1111/pedi.12184

7. Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018;19:115-135. doi: https://doi.org/10.1111/pedi.12718

8. Sundberg F, Barnard K, Cato A, et al. Managing diabetes in preschool children. Pediatr Diabetes. 2017;18(7):499-517. doi: https://doi.org/10.1111/pedi.12554

9. Cameron FJ, Garvey K, Hood KK, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence. Pediatr Diabetes. 2018;19:250-261. doi: https://doi.org/10.1111/pedi.12702

10. Goldman J, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017;33(10):1821-1831. doi: https://doi.org/10.1080/03007995.2017.1335192

11. Schmidt MI, Hadji-Georgopoulos A, Rendell M, et al. The Dawn Phenomenon, an Early Morning Glucose Rise: Implications for Diabetic Intraday Blood Glucose Variation. Diabetes Care. 1981;4(6):579-585. doi: https://doi.org/10.2337/diacare.4.6.579

12. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocrine Practice. 2005;11(1):55-64, doi: https://doi.org/10.4158/EP.11.1.55

13. Holterhus PM, Bokelmann J, Riepe F, et al. German/Austrian DPV-Initiative and the German Pediatric CSII Working Group. Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps. Diabetes Care. 2013;36(6):1507-1511. doi: https://doi.org/10.2337/dc12-1705

14. Danne T, Battelino T, Kordonouri O, et al. A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatr Diabetes. 2005;6(4):193-198. doi: https://doi.org/10.1111/j.1399-543X.2005.00131.x

15. Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr. 2002;140(2):235-240. doi: https://doi.org/10.1067/mpd.2002.120509

16. DiMeglio LA, Boyd SR, Pottorff TM, et al. Preschoolers Are Not Miniature Adolescents: A Comparison of Insulin Pump Doses in Two Groups of Children with Type 1 Diabetes Mellitus. J Pediatr Endocrinol Metab. 2004;17(6):865-870. doi: https://doi.org/10.1515/JPEM.2004.17.6.865

17. Mallad A, Hinshaw L, Dalla Man C, et al. Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches. Diabetes Technol Ther. 2015;17(8):587-595. doi: https://doi.org/10.1089/dia.2015.0011

18. Niwano F, Hiromine Y, Noso S, et al. Insulin deficiency with and without glucagon: A comparative study between total pancreatectomy and type 1 diabetes. J Diabetes Investig. 2018;9(5):1084-1090. doi: https://doi.org/10.1111/jdi.12799

19. King AB, Clark D, Wolfe GS. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. Endocr Pract. 2012;18(4):558-562. doi: https://doi.org/10.4158/EP12042.OR

20. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract. 2009;63:425-432. doi: https://doi.org/10.1111/j.1742-1241.2008.01973.x

21. Galindo RJ, Davis GM, Fayfman M, et al. Comparison of efficacy and safety of glargine and detemir insulin in the management of inpatient hyperglycemia and diabetes. Endocr Pract. 2017;23:1059-1066. doi: https://doi.org/10.4158/EP171804.OR

22. Crisher MA, Giuliano CA, Hartner CL. Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? Clin Diabetes. 2019;37(2):167-171. doi: https://doi.org/10.2337/cd18-0065

23. Capson J, Cade K, Avanesyan A. Detemir vs Glargine: Comparison of Inpatient Glycemic Control. J Am Osteopath Assoc. 2019;119(2):89-95. doi: https://doi.org/10.7556/jaoa.2019.014

24. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24(6):635-642. doi: https://doi.org/10.1111/j.1464-5491.2007.02113.x

25. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority tr. Clin Ther. 2009;31(10):2086-2097. doi: https://doi.org/10.1016/j.clinthera.2009.10.006

26. Davies M, Sasaki T, Gross JL, et al. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. Diabetes Obes Metab. 2016;18:96-99. doi: https://doi.org/10.1111/dom.12573

27. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191-204. doi: https://doi.org/10.2147/DMSO.S21979

28. Monnier L, Colette C, Wojtusciszyn A, et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care. 2017;40(7):832-838. doi: https://doi.org/10.2337/dc16-1769

29. Thalange N, Deeb L, Klingensmith G, et al. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: an analysis of data from two randomized trials. Pediatr Diabetes. 2019;20:314-320. doi: https://doi.org/10.1111/pedi.12821

30. Thalange N, Deeb L, Iotova V, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatric Diabetes. 2015;16:164-176. doi: https://doi.org/10.1111/pedi.12263

31. Knudsen ST, Lapolla A, Schultes B, et al. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EUTREAT). Diabet Med. 2019;36(7):868-877. doi: https://doi.org/10.1111/dme.13976

32. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864 2012. doi: https://doi.org/10.1111/j.1463-1326.2012.01627.x

33. Thalange N, Biester T, Danne T. Clinical use of degludec in children and adolescents with T1D: a narrative review with fictionalized case reports. Diabetes Ther. 2019;10(4):1219-1237. doi: https://doi.org/10.1007/s13300-019-0641-3

34. Thalange N, Gundgaard J, Parekh W, Tutkunkardas D. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. BMJ Open Diabetes Res Care. 2019;7:e000664. doi: https://doi.org/10.1136/bmjdrc-2019-000664